Abstract
The p53 pathway is inactivated in essentially all human tumors p53 is lost or mutated in over 50% of all human cancers, and the majority of the remaining tumors carry mutations in other components of the pathway. It appears that the main biological function of p53 in vivo is to suppress tumorigenesis, because mice with homozygous deletion of the p53 gene are normal, but develop multiple tumors at an early age. p53 plays a central role in cell cycle control and apoptosis in response to DNA damage and other stresses, and in response to oncogenic activation. Loss of p53 function leads to excessive proliferation due to an inappropriate cell cycle control, or to a reduced apoptosis and an excess survival. This allows propagation of cells with damaged DNA resulting in increased genetic instability and enhanced risk of cancer. The contribution of each of the p53 functions, or the lack thereof, to tumor initiation and progression has been studied in vivo, in genetically modified mice. Mice with deletions of one or both p53 alleles have been crossed with mice expressing dominant oncogenes, or lacking other tumor suppressor genes, in order to analyse the genetic interaction between different tumorigenic pathways in vivo. These studies have defined how oncogenic mutations can cooperate in tumorigenesis in tissue and the tumor-specific ways.
Keywords: tumor suppression, oncogene, tumorigenesis
Current Genomics
Title: Studies of p53 Tumor Suppression Activity in Mouse Models
Volume: 3 Issue: 4
Author(s): Dionisio Martin-Zanca
Affiliation:
Keywords: tumor suppression, oncogene, tumorigenesis
Abstract: The p53 pathway is inactivated in essentially all human tumors p53 is lost or mutated in over 50% of all human cancers, and the majority of the remaining tumors carry mutations in other components of the pathway. It appears that the main biological function of p53 in vivo is to suppress tumorigenesis, because mice with homozygous deletion of the p53 gene are normal, but develop multiple tumors at an early age. p53 plays a central role in cell cycle control and apoptosis in response to DNA damage and other stresses, and in response to oncogenic activation. Loss of p53 function leads to excessive proliferation due to an inappropriate cell cycle control, or to a reduced apoptosis and an excess survival. This allows propagation of cells with damaged DNA resulting in increased genetic instability and enhanced risk of cancer. The contribution of each of the p53 functions, or the lack thereof, to tumor initiation and progression has been studied in vivo, in genetically modified mice. Mice with deletions of one or both p53 alleles have been crossed with mice expressing dominant oncogenes, or lacking other tumor suppressor genes, in order to analyse the genetic interaction between different tumorigenic pathways in vivo. These studies have defined how oncogenic mutations can cooperate in tumorigenesis in tissue and the tumor-specific ways.
Export Options
About this article
Cite this article as:
Martin-Zanca Dionisio, Studies of p53 Tumor Suppression Activity in Mouse Models, Current Genomics 2002; 3 (4) . https://dx.doi.org/10.2174/1389202023350336
DOI https://dx.doi.org/10.2174/1389202023350336 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advances in Genomics and Precision Medicine for Cardiovascular Diseases
Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality globally, representing a significant challenge to public health systems. Recent advancements in genomics and precision medicine offer unprecedented opportunities to transform the prevention, diagnosis, and treatment of CVDs. This special issue of Current Genomics explores the latest developments in ...read more
AI-Driven Genomics and Multi-Omics Approaches for Drug Discovery and Precision Medicine
The rapid advancements in artificial intelligence (AI) have opened new avenues in genomics and multi-omics research, providing transformative insights into disease mechanisms, biomarker discovery, and therapeutic strategies. This thematic issue explores the intersection of AI with genomics, transcriptomics, proteomics, metabolomics, and epigenomics, focusing on how computational intelligence can facilitate data ...read more
Emerging Molecular Mechanisms in Rare Genetic Skeletal Disorders: Linking Genomic Mutations to Clinical Outcomes.
Rare genetic skeletal disorders encompass a diverse group of conditions that impact bone and cartilage development, often due to pathogenic mutations in critical developmental genes. This thematic issue aims to explore the intricate molecular mechanisms underlying these disorders, providing insights into how specific genomic mutations translate into clinical phenotypes. Recent ...read more
Related Journals

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Isoniazid: Metabolic Aspects and Toxicological Correlates
Current Drug Metabolism Intrinsic Disorder in Male Sex Determination: Disorderedness of Proteins from the Sry Transcriptional Network
Current Protein & Peptide Science Importance of Wnt Signaling in the Tumor Stroma Microenvironment
Current Cancer Drug Targets γ-Tocotrienol Induces Apoptosis in Human T Cell Lymphoma through Activation of Both Intrinsic and Extrinsic Pathways
Current Pharmaceutical Design Recent Clinical Experience with Oncolytic Viruses
Current Pharmaceutical Biotechnology The Emerging Role of Connexin 43 in Testis Pathogenesis
Current Molecular Medicine Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Towards Human on a Chip: Recent Progress and Future Perspective
Micro and Nanosystems The Emerging Role of LncRNA FENDRR in Multiple Cancers: A Review
Current Molecular Medicine Urokinase-a Very Popular Cardiovascular Agent
Recent Patents on Cardiovascular Drug Discovery Advances in Imaging Gene-Directed Enzyme Prodrug Therapy
Current Pharmaceutical Biotechnology Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Cancer Stemness as a Target for Immunotherapy is Shaped by Proinflammatory Stress
Current Stem Cell Research & Therapy Effects of Specific Cyclooxygenase-2 Inhibitors on Carcinogenesis
Medicinal Chemistry Reviews - Online (Discontinued) Dihydrofolate Reductase (DHFR) Inhibitors: A Comprehensive Review
Current Medicinal Chemistry Discussion on the Structural Modification and Anti-tumor Activity of Flavonoids
Current Topics in Medicinal Chemistry Metallothioneins and Cancer
Current Protein & Peptide Science Novel Patents and Cancer Therapies for Transforming Growth Factor- Beta and Urokinase Type Plasminogen Activator: Potential Use of Their Interplay in Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Mucin-based Targeted Pancreatic Cancer Therapy
Current Pharmaceutical Design